lenabasum   Click here for help

GtoPdb Ligand ID: 9772

Synonyms: ajulemic acid | CPL-7075 | CPL7075 | CT-3 | IP-751 | IP751
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Lenabasum (ajulemic acid) is a synthetic derivative of the non-psychoactive cannabinoid THC metabolite 11-nor-9-Carboxy-THC (PubChem CID 108207) [10]. It is a non-selective cannabinoid receptor agonist [5,7]. Lenabasum exhibits potentially useful analgesic and anti-inflammatory actions [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 66.76
Molecular weight 400.26
XLogP 6.96
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCCCCCC(c1cc(O)c2c(c1)OC(C1C2CC(=CC1)C(=O)O)(C)C)(C)C
Isomeric SMILES CCCCCCC(c1cc(O)c2c(c1)OC([C@H]1[C@H]2CC(=CC1)C(=O)O)(C)C)(C)C
InChI InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Ajulemic acid (research code JBT-101) is being evaluated as a treatment for systemic lupus erythematosus (SLE) in Phase 2 clinical trial NCT03093402.
It was also more effective in reducing chronic neuropathic pain than placebo in a Phase 2 clinical trial [6].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03093402 JBT-101 in Systemic Lupus Erythematosus (SLE) Phase 2 Interventional National Institute of Allergy and Infectious Diseases (NIAID)
NCT02466243 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Phase 2 Interventional Corbus Pharmaceuticals Inc. Primary completion of this trial is expected in September 2021, with full completion a year later. Data is likely to be shared by the end of 2021.
NCT03398837 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Phase 3 Interventional Corbus Pharmaceuticals Inc. Failure of lenabasum in this Phase 3 study in cutaneous systemic sclerosis patients was advised in September 2020.
NCT02465437 Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis Phase 2 Interventional Corbus Pharmaceuticals Inc. 8
NCT02465450 Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis Phase 2 Interventional Corbus Pharmaceuticals Inc. Despite positive indications from this study lenabasum failed to do better than placebo at reducing pulmonary exacerbations in Phase 2b cystic fibrosis trial NCT03451045. Development in CF was subsequently discontinued. 4